The Role of Antihistamines in Asthma Management

Dale HH, Laidlaw PP. The physiological action of a beta-imidazolyl-ethyl-amine. J Physiol 1910; 41: 318–44 White MV. The role of histamine in allergic diseases. J Allergy Clin Immunol 1990; 86: 599–605 Best CH, Dale HH, Dudley HW, et al. The nature of the vaso-dilator constituents of certain tissues [letter]. J Physiol 1927; 62: 397 Gravelyn TR, Pan PM, Eschenbacher WL. Mediator release in an isolated airway segment in subjects with asthma. Am Rev Respir Dis 1988; 137: 641–6 Casale TB, Wood D, Richerson HB, et al. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987; 80: 1507–11 Casale TB, Wood D, Richerson HB, et al. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest 1987; 79: 1197–203 Louis R, Van Tulder L, Poncelet M, et al. Correlation between bronchoalveolar lavage (BAL) fluid cell lysate histamine content and BAL fluid eosinophil count in atopic and nonatopic asthmatics. Int Arch Allergy Immunol 1997; 112: 309–12 Popa VT. Bronchodilating activity of an H1 blocker, chlorpheniramine. J Allergy Clin Immunol 1977; 59: 54–63 Popa VT. Effect of an H1 blocker, chlorpheniramine, on inhalation tests with histamine and allergen in allergic asthma. Chest 1980; 78: 442–51 Bousquet J, Godard P, Michel FB. Antihistamines in the treatment of asthma. Eur Respir J 1992; 5: 1137–42 Schuller DE. Adverse effects of brompheniramine on pulmonary function in a subset of asthmatic children. J Allergy Clin Immunol 1983; 72: 175–9 Simons FE, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996; 26: 1092–7 Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol 1980; 69: 663–7 Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy 2000; 55 Suppl. 64: 17–27 Marshall Jr GD. Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents. J Allergy Clin Immunol 2000; 106: S303–9 Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs 2001; 61: 207–36 Marone G, Granata F, Spadaro G, et al. The histamine-cytokine network in allergic inflammation. J Allergy Clin Immunol 2003; 112: S83–8 Arnold R, Rihoux J, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999; 29: 1681–91 Lippert U, Moller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000; 9: 118–24 Triggiani M, Gentile M, Secondo A, et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 2001; 166: 4083–91 Bakker RA, Wieland K, Timmerman H, et al. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur J Pharmacol 2000; 387: R5–7 Abdelaziz MM, Devalia JL, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 1998; 101: 410–20 Papi A, Papadopoulos NG, Stanciu LA, et al. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001; 108: 221–8 Ciprandi G, Pronzato C, Ricca V, et al. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy. Clin Exp Allergy 1995; 25: 871–8 Ciprandi G, Pronzato C, Ricca V, et al. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. Clin Exp Allergy 1997; 27: 1175–83 Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996; 98: 1088–96 Ciprandi G, Tosca M, Ricca V, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy 1997; 27: 1160–6 Redier H, Chanez P, De Vos C, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol 1992; 90: 215–24 Bryce PJ, Geha R, Oettgen HC. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J Allergy Clin Immunol 2003; 112: 149–58 Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998; 9: 116–24 Wood-Baker R, Holgate ST. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993; 91(5): 1005–14 MacFarlane PI, Heaf DP. Selective histamine blockade in childhood asthma; the effect of terfenadine on resting bronchial tone and exercise induced bronchoconstriction. Respir Med 1989; 83: 19–24 Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. J Allergy Clin Immunol 1995; 96: 174–81 Lee DK, Bates CE, Currie GP, et al. Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol 2003; 111: 337–41 Finnerty JP, Holgate ST. Evidence for the roles of histamine and prostaglandins as mediators in exercise-induced asthma: the inhibitory effect of terfenadine and flurbiprofen alone and in combination. Eur Respir J 1990; 3: 540–7 Magnussen H, Reuss G, Jorres R, et al. The effect of azelastine on exercise-induced asthma. Chest 1988; 93: 937–40 Baki A, Orhan F. The effect of loratadine in exercise-induced asthma. Arch Dis Child 2002; 86: 38–9 Ghosh SK, De Vos C, McIlroy I, et al. Effect of cetirizine on exercise induced asthma. Thorax 1991; 46: 242–4 Bentley AM, Walker S, Hanotte F, et al. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clin Exp Allergy 1996; 26: 909–17 Rafferty P, Ghosh SK, De Vos C, et al. Effect of oral and inhaled cetirizine in allergen induced bronchoconstriction. Clin Exp Allergy 1993; 23: 528–31 Twentyman OP, Ollier S, Holgate ST. The effect of H1-receptor blockade on the development of early- and late-phase bronchoconstriction and increased bronchial responsiveness in allergen-induced asthma. J Allergy Clin Immunol 1993; 91: 1169–78 Town GI, Holgate ST. Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. J Allergy Clin Immunol 1990; 86: 886–93 Hamid M, Rafferty P, Holgate ST. The inhibitory effect of terfenadine and flurbiprofen on early and late-phase bronchoconstriction following allergen challenge in atopic asthma. Clin Exp Allergy 1990; 20: 261–7 Balzano G, Gallo C, Masi C, et al. Effect of azelastine on the seasonal increase in non-specific bronchial responsiveness to methacholine in pollen allergic patients: a randomized, double-blind placebo-controlled, crossover study. Clin Exp Allergy 1992; 22: 371–7 Finnerty JP, Holgate ST, Rihoux JP. The effect of 2 weeks treatment with cetirizine on bronchial reactivity to methacholine in asthma. Br J Clin Pharmacol 1990; 29: 79–84 Ruffin RE, Latimer KM. Lack of effect of 4 weeks of oral H1 antagonist on bronchial responsiveness. Eur Respir J 1991; 4: 575–9 Aubier M, Neukirch C, Peiffer C, et al. Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy 2001; 56: 35–42 Bruin-Weller MS, Rijssenbeek-Nouwens LH, de Monchy JG. Lack of effect of cetirizine on early and late asthmatic response after allergen challenge. J Allergy Clin Immunol 1994; 94: 231–9 Van Den Berg M, Meijer RJ, Kerstjens HA, et al. PC20 adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine. Am J Respir Crit Care Med 2001; 163: 1546–50 Phillips GD, Polosa R, Holgate ST. The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma. Clin Exp Allergy 1989; 19: 405–9 Phillips GD, Rafferty P, Beasley R, et al. Effect of oral terfenadine on the bronchoconstrictor response to inhaled histamine and adenosine 5′-monophosphate in non-atopic asthma. Thorax 1987; 42: 939–45 Azevedo M, da Costa JT, Fontes P, et al. Effect of terfenadine and ipratropium bromide on ultrasonically nebulized distilled water-induced asthma. J Int Med Res 1990; 18: 37–49 Finnerty JP, Wilmot C, Holgate ST. Inhibition of hypertonic saline-induced bronchoconstriction by terfenadine and flurbiprofen: evidence for the predominant role of histamine. Am Rev Respir Dis 1989; 140: 593–7 Lee DK, Jackson CM, Haggart K, et al. Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest 2004; 125: 1372–7 Fardon TC, Lee DK, Hodge MR, et al. Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Ann Allergy Asthma Immuol 2005; 95: 259–65 Van Ganse E, Kaufman L, Derde MP, et al. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997; 10: 2216–24 Nelson HS. Prospects for antihistamines in the treatment of asthma. J Allergy Clin Immunol 2003; 112: S96–100 Bruttmann G, Pedrali P, Arendt C, et al. Protective effect of cetirizine in patients suffering from pollen asthma. Ann Allergy 1990; 64: 224–8 Dijkman JH, Hekking PR, Molkenboer JF, et al. Prophylactic treatment of grass pollen-induced asthma with cetirizine. Clin Exp Allergy 1990; 20: 483–90 Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76: 440–6 Bousquet J, Emonot A, Germouty J, et al. Double-blind multicenter study of cetirizine in grass-pollen-induced asthma. Ann Allergy 1990; 65: 504–8 Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1995; 95: 923–32 Rafferty P, Jackson L, Smith R, et al. Terfenadine, a potent histamine H1-receptor antagonist in the treatment of grass pollen sensitive asthma. Br J Clin Pharmacol 1990; 30: 229–35 Taytard A, Beaumont D, Pujet JC, et al. Treatment of bronchial asthma with terfenadine; a randomized controlled trial. Br J Clin Pharmacol 1987; 24: 743–6 Wood-Baker R, Smith R, Holgate ST. A double-blind, placebo controlled study of the effect of the specific histamine H1-receptor antagonist, terfenadine, in chronic severe asthma. Br J Clin Pharmacol 1995; 39: 671–5 Busse WW, Middleton E, Storms W, et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med 1996; 153: 122–7 Gould CA, Ollier S, Aurich R, et al. A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. Br J Clin Pharmacol 1988; 26: 515–25 Balzano G, Gallo C, Masi C, et al. Effect of azelastine on the seasonal increase in non-specific bronchial responsiveness to methacholine in pollen allergic patients: a randomized, double-blind placebo-controlled, crossover study. Clin Exp Allergy 1992; 22: 371–7 Ekstrom T, Osterman K, Zetterstrom O. Lack of effect of loratadine on moderate to severe asthma. Ann Allergy Asthma Immunol 1995; 75: 287–9 Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56 Suppl. 65: 21–7 Baena-Cagnani CE, Berger WE, DuBuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003; 130: 307–13 Spector S, Lee N, McNutt B, et al. Effect of terfenadine in asthmatic patients. Ann Allergy 1992; 69: 212–6 Ghosh SK, De Vos C, Mcllroy I, et al. Effect of cetirizine on histamine- and leukotriene D4-induced bronchoconstriction in patients with atopic asthma. J Allergy Clin Immunol 1991; 87: 1010–3 Gong Jr H, Tashkin DP, Dauphinee B, et al. Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1990; 85: 632–41 Lee DK, Gray RD, Wilson AM, et al. Single and short-term soing effect of levocetirizine on adenosine monophosphate bronchoprotection in atopic asthma. Br J Clin Pharmacol 2004; 58: 34–9 Bustos GJ, Bustos D, Bustos GJ, et al. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy 1995; 25: 568–73 Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol 2001; 108: 929–37 Sampson AP, Rorke S. Combination therapy with anti-mediator drugs in allergic disease. Clin Exp Allergy 2001; 31: 11–7 Ruck LM, Rizzo CA, Anthes JC, et al. Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus. Life Sci 2001; 68: 2825–34 Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997; 155: 1856–63 Reicin A, White R, Weinstein SF, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 2000; 160: 2481–8 Brannan JD, Anderson SD, Gomes K, et al. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420–5 Eggleston PA, Kagey-Sobotka A, Lichtenstein LM. A comparison of the osmotic activation of basophils and human lung mast cells. Am Rev Respir Dis 1987; 135: 1043–8 Brannan JD, Koskela H, Anderson SD, et al. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. Am J Respir Crit Care Med 1998; 158: 1120–6 Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: 406–12 Currie GP, Haggart K, Lee DK, et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy 2003; 33: 783–8 David BE, Todd DC, Cockcroft DW. Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. J Allergy Clin Immunol 2005; 116: 768–72 Peroni DG, Piacentini GL, Pietrobelli A, et al. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. Eur Respir J 2002; 20: 104–7 Dahlen B, Roquet A, Inman MD, et al. Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. J Allergy Clin Immunol 2002; 109: 789–93 Eggleston PA, Kagey-Sobotka A, Schleimer RP, et al. Interaction between hyper-osmolar and IgE-mediated histamine release from basophils and mast cells. Am Rev Respir Dis 1984; 130: 86–91 Lordan JL, Holgate ST. H1-antihistamines in asthma. Clin Allergy Immunol 2002; 17: 221–48 Anderson SD, Brannan JD. Exercise-induced asthma: is there still a case for histamine? J Allergy Clin Immunol 2002; 109: 771–3 Wilson AM, Orr LC, Sims EJ, et al. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000; 162: 1297–301 Vignola AM, Bousquet J. Rhinitis and asthma: a continuum of disease? Clin Exp Allergy 2001; 31: 674–7 Lieberman P. A pathophysiologic link between allergic rhinitis and asthma. Pediatr Ann 2000; 29: 405–10 Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999; 104: 534–40 Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: S781–6 Foresi A, Pelucchi A, Gherson G, et al. Once daily intranasal fluticasone propionate (200 μg) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996; 98: 274–82 Adams RJ, Fuhlbrigge AL, Finkelstein JA, et al. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109: 636–42 Corren J, Manning BE, Thompson SF, et al. Rhinitis therapy and the rpevention of hospital care for ashtma: case-control study. J Allergy Clin Immunol 2004; 113: 415–9